Introduction
The majority of patients with myelodysplastic syndromes (MDS) have normal to increased bone marrow cellularity at diagnosis, but 5-20% of patients will present with hypocellular marrows. [1] [2] [3] Patients with hypoplastic myelodysplastic syndromes (hMDS) may initially be difficult to distinguish from those with aplastic anemia (AA) because the clinical and pathologic findings in each of these disorders may overlap. Erythroid dysplasia is a hallmark of MDS, but this finding alone cannot reliably exclude AA as it is also not uncommon in this disease. 4, 5 Moreover, an accurate morphological analysis may be difficult to perform because of inadequate diagnostic material from hypoplastic specimens. Clonal cytogenetic abnormalities are usually considered diagnostic of MDS, but these defects are typically found in only half of all MDS cases and cytogenetic analyses may be less reliable when the bone marrow is hypocellular. 6 Despite the difficulty distinguishing hMDS from AA, an accurate diagnosis has important clinical implications since patients with hMDS have a greater risk of neoplastic progression 2, 3, 7 and treatment for the two disorders can be quite different. 8 
CD34
þ hematopoietic progenitors are central to the pathogenesis of both MDS and AA.
5 CD34 þ cells normally comprise an average of 1À2% (range 0.5À5%) of the bone marrow cellularity, but are significantly decreased in AA bone marrow [9] [10] [11] because they are the targets of autoimmune destruction. 5, 12 In contrast, CD34
þ cells appear to be the cells from which MDS originate, 5, 13, 14 and thus may be increased as a result of neoplastic clonal expansion. The potential quantitative difference between CD34
þ bone marrow cells in hMDS and AA suggest that this parameter may be used to distinguish between these two disorders. Therefore, we analyzed the percentage of CD34 þ cells in patients presenting with pancytopenia and hypocellular bone marrows, and correlated these findings with clinical outcomes.
Materials and methods

Patients
Records of adult patients referred to the Johns Hopkins Oncology Center between 1998 and 2002 for evaluation of pancytopenia or a presumptive diagnosis of MDS or AA were reviewed. Patients were included in this study if they had low peripheral blood counts involving at least two lineages and consistent with a clinical diagnosis of AA: white blood cell count p3 500/ml, platelet count of p100 000/ml, or hemoglobin value p10 g/dl with a reticulocyte count p30 000/mm 3, 15 The low blood counts also had to be accompanied by a hypoplastic bone marrow (o30% cellularity, or o20% if older than 60 years) without an increase in blasts (o5%) or ringed sideroblasts on routine morphologic examination. Analyses were limited to each patient's initial diagnostic specimen. The Institutional Review Board of the Johns Hopkins Hospital approved this retrospective review.
CD34
þ cell analysis CD34 þ bone marrow cells were quantified as the percentage of marrow mononuclear cells by multicolor flow cytometry of bone marrow aspirates using a sequential gating strategy with CD45-perCP, CD34-PE and CD71-FITC (to identify and include nucleated red cells). 16 Patients whose samples lacked CD71 bright CD45 negative nucleated red cells and normal B-cell precursors 17 were considered to have specimens highly contaminated by peripheral blood. In these patients and others in whom aspirates were not available because the marrows were performed at an outside institution, CD34 þ cells were quantified by immunohistochemistry of bone marrow biopsies; a minimum of 500 nucleated cells on the biopsies were counted, using a mouse antihuman CD34 avidin-conjugated monoclonal antibody followed by biotin-linked immunoperoxidase staining (BeckmanCoulter, Hialeah, FL, USA). Pathologists determining the CD34 percentages by both flow cytometry and immunohistochemistry were blinded to any clinical information on the patients.
Statistical analysis
Values are expressed as the mean7standard error of the mean (s.e.m.) or median with range. Differences between groups were analyzed by Student's t-test.
Results
We retrospectively evaluated the diagnostic bone marrow samples from the 35 patients who presented with pancytopenia and were found to have an associated hypocellular bone marrow without increased blasts or ringed sideroblasts on routine morphologic examination ( Table 1) . Of the 35 patients, 29 had bone marrow aspirates examined by flow cytometry, whereas there were no aspirates for CD34 determination in the remaining six patients. Of the aspirates, four (14%) were thought to represent samples extensively contaminated with peripheral blood rather than true marrow specimens because they lacked CD71 bright CD45 negative nucleated red cells and normal B-cell precursors. 17 Quantitative analysis of the 25 adequate aspirate samples revealed that eight (32%) displayed normal or increased percentages (X1%) of CD34 þ cells, whereas the remaining 17 (68%) had low (o0.5%) CD34 þ cell counts. In the 10 patients with unavailable (n ¼ 6) or inadequate (n ¼ 4) bone marrow aspirates, immunohistochemical staining for CD34 was performed on the bone marrow biopsies. The percentage of CD34 þ cells was normal or increased in seven (70%) of these patients and low in three (30%). Therefore, in the 35 patients studied, 15 had normal or high CD34 þ counts and 20 had low CD34 þ counts.
Of the 35 patients, 15 ( Table 1 , Patients 1-15) were eventually diagnosed as having hMDS: seven patients had identifiable cytogenetic abnormalities typical for MDS at presentation, and eight with normal cytogenetics progressed to refractory anemia with excess blasts (RAEB) or AML with followup. All four patients with marrow trilineage dysplasia exhibited neoplastic progression. Patients 16-32 (Table 1 ) met clinical criteria, 15 and were treated, for AA: 10 with high-dose cyclophosphamide, 18, 19 four with immunosuppressive therapy (antithymocyte globulin and/or cyclosporine), 20 and three with allogeneic transplantation after high-dose cyclophosphamide conditioning. 21 None of these 17 patients has shown any evidence of neoplastic progression, and only two have died, both ( Table 1 , Patients 28 and 29) with refractory neutropenia and infection while on immunosupporessive therapy. Of the 17 patients treated for AA, eight are currently in a complete remission (complete normalization of blood counts), six are in a partial remission (neutrophil count 40.5 Â 10 9 cells/l without growth factor support and transfusion independent), and three did not respond. An additional three patients ( 
Discussion
Distinguishing hMDS and AA remains a clinical dilemma, as there are no diagnostic criteria that can completely separate these two diseases. Marrow trilineage dysplasia heralded neoplastic progression, but was an uncommon finding in our series. Although marrow cellularity tended to be lower in the patients treated as AA (Table 1) , the degree of marrow hypocellularity showed complete overlap with the MDS patients. Moreover, marrow cellularity in AA can be quite patchy, 5 making it an unreliable discriminator. Even clonal cytogenetic abnormalities, usually considered an exclusion criterion for AA, have not precluded this diagnosis at some centers. 8, 22, 23 MDS also evolves out of AA in about 10-20% of patients. 20, 24, 25 Moreover, both diseases may have a similar pathophysiology, 5, 8, 26 and immunosuppressive therapy may benefit some patients with hMDS. 27, 28 Despite the close relationship between AA and hMDS, there are important differences between the two diseases. Patients with clonal cytogenetics that evolve out of AA have high rates of progression to RAEB or AML, and about half will die within 2 years. 7 Clonal cytogenetic changes in the setting of AA rarely if ever resolve, 8 and immunosuppression's role in MDS remains controversial especially for certain cytogenetic changes (i.e., abnormalities of chromosomes 5 and 7). 7, 8, 29 Thus, critical prognostic and therapeutic considerations require accurate differentiation between hMDS and AA if possible.
All 15 patients with abnormal cytogenetics or neoplastic progression during follow-up had normal or elevated marrow CD34 percentages at initial presentation. In contrast, all 17 patients treated for AA exhibited low CD34 counts, and none have progressed to MDS or AML. Moreover, these two groups showed no overlap in their marrow CD34 numbers. Three patients ( Table 1 , Patients 33-35) in our series had normal cytogenetics and low CD34 counts, but without life-threatening blood counts that required therapy. All three of these patients have remained stable without evidence of neoplastic progression with follow-up. These patients may have moderate AA, a less severe form of AA that can persist for months or years, progress to more severe disease, or even resolve spontaneously. 5, 30, 31 As some cases of moderate AA 5, 30, 31 and lowgrade MDS (e.g., the 5qÀ syndrome 32, 33 ) never progress to CD34 counts in AA and hypoplastic MD WH Matsui et al þ cell counts. 9, 10, 36, 37 However, significant overlap in the CD34 percentages between these two disorders has precluded using this assay diagnostically. 9, 10, 36, 37 Technical issues and difficulty precisely diagnosing AA and hMDS may account for the differences between previous reports and our findings. Low CD34 þ cell percentages seen in some hMDS patients in other studies may have been the result of contamination of bone marrow aspirates with peripheral blood, as there was no description of criteria for validating the quality of their marrow samples. 9, 36, 37 We only considered marrow aspirate samples adequate if normal B cell and nucleated red cell precursors could be identified. Although Orazi et al 10 found that bone marrow biopsies from some hMDS patients also displayed low percentages of CD34 þ cells by immunohistochemistry, many of their patients had normal cytogenetics and no clinical outcome was provided; thus, these patients may have been misclassified. The development of diagnostic tests in diseases that lack definitive diagnostic criteria is obviously problematic. Moreover, there may not always be an unequivocal clinical distinction between hMDS and AA, as illustrated by the cases of MDS that evolve from AA. 20, 24, 25 Nevertheless, our results suggest that the quantification of CD34 þ cells in the marrow of such patients may allow accurate differentiation between AA and hMDS.
